AINEWS
TuHURA files to test a VISTA-blocking antibody in leukemia
The immune checkpoint target has a mixed record in solid tumors. An Investigational New Drug application is the regulatory step before human trials, not proof the drug works.
The immune checkpoint target has a mixed record in solid tumors. An Investigational New Drug application is the regulatory step before human trials, not proof the drug works.
TuHURA Biosciences has asked the U.S. Food and Drug Administration for permission to begin human trials of TBS-2025, an antibody designed to block VISTA, a molecular "off switch" some tumors use to hide from the immune system. The June 15 announcement, delivered via PRNewswire, targets acute myeloid leukemia and related blood cancers. An Investigational New Drug application is the regulatory step required before a drug is tested in people. It is not an approval, not an efficacy result, and not a treatment.
That distinction matters because VISTA is a checkpoint target with a complicated history. Earlier solid-tumor programs in the same drug class have not produced a clear winner, which is part of why a move into blood cancers is a real scientific question rather than a safe next step. TuHURA's bet is that the mechanism might behave differently in leukemia, where the immune environment is structured differently than in solid tumors. The "first to advance" framing in the company's press release is exactly that: a company framing, not a confirmed scientific first.
The planned trial design says something specific about which patients TuHURA thinks the drug might help. According to the release, the Phase 1b/2 study will enroll acute myeloid leukemia (AML) patients whose disease carries NPM1 or FLT3-ITD mutations, two of the most common genetic drivers of the disease, and is expected to add patients with relapsed or refractory high-risk MDS, a related blood-disorder diagnosis. TuHURA cites company estimates that these subsets together represent roughly 60 to 70 percent of AML patients. The company also plans to test TBS-2025 in combination with menin inhibitors, a newer class of targeted drugs that has begun to reshape AML treatment, with the implicit argument that releasing the immune brake and hitting the cancer's growth machinery at the same time could be more effective than either alone.
Two pieces of the announcement are worth flagging as company claims rather than settled facts. First, the "first to advance a VISTA-inhibiting antibody" claim appears in the June 15 PRNewswire release without independent verification. Second, the combined Phase 1b/2 design and the company's projection of saving "four to six months" of development time reflect a target, not a confirmed schedule. Phase 1b/2 study initiation is a company-stated H2 2026 goal.
The regulatory back-and-forth behind the filing is also worth a sentence. TuHURA filed an IND earlier in 2026 and, according to the release, the FDA later told the company that the requested Type B / pre-IND-style meeting was not necessary and that the agency would instead provide written responses to the company's questions about the proposed Phase 1b/2 plan. The current IND follows that feedback. A written-response path is procedurally normal, but it does not by itself signal FDA enthusiasm for the program.
For the broader VISTA field, the question is not whether TBS-2025 will work, which no one outside a clinic can answer today, but whether the target behaves differently in liquid tumors than it did in solid ones. AML and MDS originate and live in the bone marrow, where immune cells, including the T cells that checkpoint drugs are meant to reactivate, are abundant and behave differently than they do in lung or colon tissue. The scientific case for the move rests on that contrast. The proof will be in the first dose-escalation cohorts, when TBS-2025 is given to a small number of patients and researchers can finally measure whether the antibody does what the company says it does.